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A 33-years old patient gravida 5 with chronic hypertension, 
hypothyroidism, polycystic ovarian syndrome with insuline resist-
ance and obesity (BMI 32) was offered an experimental admin-
istration of pravastatin due to multiple pregnancy losses (fetal 
demise at 6, 8, 18 and 22 weeks) and preeclampsia in the last 
pregnancy. From the early first trimester methyldopa (750 mg/day), 
metformin (850 mg/day), L-thyroxine (50 µg/day), acetylsalicylic acid 
(150 mg/day) and enoxaparin (40 µg/day) were administered. First 
trimester risk assessment after combined test revealed low risk of 
chromosomal abnormalities with high risk of preeclampsia and fetal 
growth restriction: pregnancy associated plasma protein A (PAPP-A) 
serum level corresponding to 0.294 multiple of median (MoM) and 
high pulsatility indices in uterine arteries. At 17 weeks of gestation 
pravastatin (20 mg/day) was included to the treatment as a pre-
ventive modality from preeclampsia and intrauterine fetal demise 
(IUFD). Before administration of the pravastatin, patient gave written 
consent and this management was accepted by Ethical Comit-
tee of Medical University of Warsaw. Anomaly scan did not reveal 
any abnormalities. At 27 weeks of gestation patient was admitted 
to the hospital due to cervical insufficiency with estimated fetal 
weight corresponding to 12th centile, normal volume of amniotic 
fluid and cerebroplacental ratio (CPR). Due to high risk of preterm 
delivery, cervical pessary and course of 24 mg betamethasone i.m. 
were administered. Throughout prental surveillance we observed 
fetal growth restriction (FGR) with decreasing volume of amniotic 
fluid, brain sparing and decreasing short time variability (STV) in 
cardiotocography (Figure 1). At 33 weeks of gestation, due to high 
risk of intrauterine fetal demise, the caesarean section was per-
formed. A female newborn was delivered in good general condition 
(10 points in Apgar score) with birthweight 1545 grams. Postnatal 
placental examination revealed morphologically normal placenta 
with weight 245 grams (corresponding to 10th centile at this gestational age), three vessels umbilical cord and marginal 
cord insertion (Figure 2). Subsequently, newborn was transferred to Neonatal Intensive Care Unit (NICU). Due to transient 
respiratory adaptation problems a nasal continuonus positive airways pressure (nCPAP) was administered for 5 days. Dur-
ing the stay in NICU an anemia and increased thyroid stymulating hormone (TSH) concentration were detected. After 
Figure 1. Increased pulsatility index (PI) (> 95th centile) in 
umbilical artery at 33 weeks of gestation
Figure 2. Postnatal, dye injection examination 
revealed three vessels in umbilical cord and marginal 
cord insertion. Placental mass weight 245 grams 
corresponding to 10th centile
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28 days, the neonate was discharged from Neonatal Department with body weight 2040 grams. Currently, the infant 
develops normally and remains under care of Pediatric Out Patient Department. 
To our knowledge, this is the first case of pravastatin admnistration in Poland in high risk pregnant woman. Due 
to side effects, statins are not routinely administered in pregnancy, however, such an experimental approach may be 
considered in patients with recurrent, early onset preeclampsia resulting in pregnancy failure. Beneficial impact of the 
pravastatin may prevail the side effects in specific group of patients, nonetheless more studies need to be undertaken 
to include this management in routine clinical practice.
